Recursion Pharmaceuticals Inc (RXRX)
8.99
-0.17
(-1.86%)
USD |
NASDAQ |
May 28, 16:00
9.00
+0.01
(+0.11%)
After-Hours: 20:00
Recursion Pharmaceuticals Shareholders Equity (Quarterly): 401.15M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 401.15M |
December 31, 2023 | 463.44M |
September 30, 2023 | 437.97M |
June 30, 2023 | 468.96M |
March 31, 2023 | 430.18M |
December 31, 2022 | 485.81M |
September 30, 2022 | 388.03M |
Date | Value |
---|---|
June 30, 2022 | 437.58M |
March 31, 2022 | 493.57M |
December 31, 2021 | 542.94M |
September 30, 2021 | 599.03M |
June 30, 2021 | 642.71M |
March 31, 2021 | -233.03M |
December 31, 2020 | -206.29M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-233.03M
Minimum
Mar 2021
642.71M
Maximum
Jun 2021
382.29M
Average
450.70M
Median
Shareholders Equity (Quarterly) Benchmarks
Eli Lilly and Co | 12.81B |
Viking Therapeutics Inc | 933.89M |
Palatin Technologies Inc | 1.579M |
Oragenics Inc | 2.625M |
Actinium Pharmaceuticals Inc | 43.86M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 557.85M |
Total Liabilities (Quarterly) | 156.70M |
Debt to Equity Ratio | 0.0028 |
Current Ratio | 4.648 |
Net Debt Paydown Yield | -0.00% |